CVRX INC (CVRX)
Sector: Health Care
2026 Annual Meeting Analysis
CVRX INC · Meeting: June 1, 2026
Directors FOR
3
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Three Class II Directors to Serve Until the 2029 Annual Meeting
New nominee with no prior board tenure at CVRx; exempt from TSR trigger as he has not yet served, and brings extensive relevant medical device executive experience including CEO roles at multiple med-tech companies.
CVRx's CEO and director since December 2022 (roughly 3.5 years); the 3-year TSR gap vs. the IHI — iShares US Medical Devices ETF is -18.1pp, which does not meet the 30pp threshold required to trigger a AGAINST vote for companies with negative absolute 3-year TSR, so no TSR trigger fires.
Long-serving director since 2008 with deep life sciences finance expertise; the 3-year TSR gap vs. the IHI — iShares US Medical Devices ETF is -18.1pp, below the 30pp threshold needed to trigger a AGAINST vote, so no TSR concerns apply; no overboarding, attendance, or independence issues identified.
All three Class II nominees pass policy screens: the TSR underperformance gap of -18.1pp vs. the IHI — iShares US Medical Devices ETF falls short of the 30pp trigger threshold for companies with negative absolute 3-year returns, no overboarding issues exist, meeting attendance was 75% or above for all directors, and no independence or familial relationship concerns were identified.
Say on Pay
✓ FORCEO
Kevin Hykes
Total Comp
$3,905,801
Prior Support
N/A
CVRx is an emerging growth company and is not required to hold a Say on Pay vote; no such proposal appears on this ballot, so this entry reflects that the proposal is absent from the filing. Because no Say on Pay vote is presented, no policy analysis is triggered and no vote determination is required.
Auditor Ratification
✓ FORAuditor
Grant Thornton LLP
Tenure
10 yrs
Audit Fees
$333,760
Non-Audit Fees
$0
Grant Thornton has served since 2016 (approximately 10 years), well below the 25-year tenure threshold; non-audit fees are zero, so the non-audit fee ratio is 0% — far below the 50% concern threshold; and Grant Thornton is a large national firm appropriate for CVRx's roughly $190M market cap company.
Overall Assessment
The 2026 CVRx annual meeting presents two substantive proposals: election of three Class II directors and ratification of Grant Thornton as auditor. All director nominees and the auditor pass applicable policy screens, resulting in FOR votes across the board; no Say on Pay vote is included because CVRx remains an emerging growth company exempt from that requirement.